Provided by Tiger Fintech (Singapore) Pte. Ltd.

I-MAB

0.8550
+0.00981.16%
Post-market: 0.8205-0.0345-4.04%17:33 EDT
Volume:103.97K
Turnover:86.52K
Market Cap:69.68M
PE:-3.12
High:0.8567
Open:0.8070
Low:0.8012
Close:0.8452
Loading ...

I-Mab Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Nov 2024

IMAB Q3 GAAP EPS Of $(0.11) Vs. $(0.04) YoY, Cash And Cash Equivalents, And Short-term Investments Of $184.4M Expected To Be Sufficient To Fund Its Current Operating Plan Into 2027

Benzinga
·
14 Nov 2024

I-Mab: Estimated Cash Runway Into 2027, Based on $184.4 Mln in Cash & Cash Equivalents, & Short-Term Investments as of Sept30, 2024

THOMSON REUTERS
·
14 Nov 2024

Press Release: I-Mab Reports Third Quarter 2024 Results

Dow Jones
·
14 Nov 2024

I-Mab: Qtrly Net Loss per Ads $0.25

THOMSON REUTERS
·
14 Nov 2024

I-Mab expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
12 Nov 2024

I-Mab Makes Interim CEO Sean Fu Permanent

MT Newswires Live
·
06 Nov 2024

I-Mab Appoints New CEO to Drive Cancer Therapy Goals

TIPRANKS
·
06 Nov 2024

I-Mab Appoints Sean Fu, Phd, MBA, as Chief Executive Officer

THOMSON REUTERS
·
06 Nov 2024

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

PR Newswire
·
06 Nov 2024

I-Mab - on Nov 1 Federal Jury Found in Favor of Defendants in Bifurcated Trial Relating to Some of Co's Trade Secret Information

THOMSON REUTERS
·
06 Nov 2024

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

PR Newswire
·
31 Oct 2024

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

PR Newswire
·
30 Oct 2024

I-Mab to Participate at the Truist Securities BioPharma Symposium

PR Newswire
·
28 Oct 2024

I-Mab Biopharma’s Strategic US Transition and Pipeline Focus

TipRanks
·
25 Oct 2024